Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface

Autor: HaoRan Tang, Leo Leung, Grazia Saturno, Amaya Viros, Duncan Smith, Gianpiero Di Leva, Eamonn Morrison, Dan Niculescu-Duvaz, Filipa Lopes, Louise Johnson, Nathalie Dhomen, Caroline Springer, Richard Marais

Publikováno v: Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)

Lysyl oxidase is able to remodel the extracellular matrix and its expression correlates with poor prognosis. Here the authors show that this protein modulates trapping of the epidermal growth factor receptor at the cell surface, causing persistent si

Externí odkaz: https://doaj.org/article/1e8df04e596541cea30f865991c28ab1

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Autor: Bryan W Miller, Jennifer P Morton, Mark Pinese, Grazia Saturno, Nigel B Jamieson, Ewan McGhee, Paul Timpson, Joshua Leach, Lynn McGarry, Emma Shanks, Peter Bailey, David Chang, Karin Oien, Saadia Karim, Amy Au, Colin Steele, Christopher Ross Carter, Colin McKay, Kurt Anderson, Thomas R Jeffry Evans, Richard Marais, Caroline Springer, Andrew Biankin, Janine T Erler, Owen J Sansom

Publikováno v: EMBO Molecular Medicine, Vol 7, Iss 8, Pp 1063-1076 (2015)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer‐related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pa

Externí odkaz: https://doaj.org/article/34d487ab4e35409d91ce088f409d4cf7

Supplementary Methods from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma

Autor: Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, Maria Romina Girotti

Supplementary Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a80fee60399dc89e1e38bb601f2a4c9
https://doi.org/10.1158/2159-8290.22531451

Abstract 4036: NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma

Autor: Grazia Saturno, Michele Modugno, Paolo Orsini, Giovanni Cervi, Laura Buffa, Ilaria Motto, Nilla Avanzi, Marisa Montemartini, Fabio Gasparri, Gemma Texido, Arturo Galvani, Antonella Isacchi

Publikováno v: Cancer Research. 83:4036-4036

The B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell malignancies, such as Chronic Lymphocytic Leukaemia (CLL) and Non-Hodgkin’s Lymphomas (NHL) including Diffuse Large B-cell Lymphomas (DLBCL). Small molecule

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1dcc00893d2c51aba759edc439edc30
https://doi.org/10.1158/1538-7445.am2023-4036

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Autor: Richard Marais, Grazia Saturno, Robert McLeary, Cyril Fisher, Udai Banerji, Alfonso Zambon, Lawrence Davies, Rebecca Lee, J.M.G. Larkin, Natasha Preece, Emma Dean, Paul Lorigan, Dan Niculescu-Duvaz, Matthew G Krebs, Amaya Viros, Nathalie Dhomen, Malin Pedersen, L. Johnson, Filipa Lopes, Caroline J. Springer, D. Holovanchuk, M. E. Gore, Ion Niculescu-Duvaz

Publikováno v: Annals of Oncology
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483

Background KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9dd4c81e95c2a5d81da34368a411222
http://europepmc.org/articles/PMC7839839